NCT05965700View on ClinicalTrials.gov

NVG-291 in Spinal Cord Injury Subjects

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

August 8, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2026

Conditions

Spinal Cord InjuriesChronic Spinal Cord InjurySubacute Spinal Cord Injury

Interventions

DRUG

NVG-291

A once daily injection

Trial Locations (1)

60611

RECRUITING

Shirley Ryan AbilityLab, Chicago

Sponsors

Lead Sponsor

All Listed Sponsors

lead

NervGen Pharma

INDUSTRY

NCT05965700 - NVG-291 in Spinal Cord Injury Subjects | Biotech Hunter | Biotech Hunter